Los Angeles-based Cedars-Sinai Medical Center could receive $800 million in the coming months if Merck completes its acquisition of Prometheus Biosciences, which develops precision therapies for immune-mediated diseases, according to an April 19 Pensions & Investments report.
Read the full post on Becker's Hospital Review - Healthcare News
